Business
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Annual General Meeting held today in Lyon, France. Among the adopted resolutions were the approval of the 2024 financial statements, delegations for the Board of Directors to increase Valneva’s share capital and/or issue financial instruments, the appointment of
About this update from Valneva Se
[{"type":"image","alt":"VALNEVA","displaySize":"","headline":null,"caption":"VALNEVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9l2h5dKc1PlSY26lXUAWsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6","width":300,"height":44}},"lazy":false},{"type":"text","content":"Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Annual General Meeting held today in Lyon, France.","length":288,"tagName":"p"},{"type":"text","content":"Among the adopted resolutions were the approval of the 2024 financial statements, delegations for the Board of Directors to increase Valneva’s share capital and/or issue financial instruments, the appointment of Dr. Gerd Zettlmeissl to the Board for a three-year term and the reappointment of Mr. James Sulat for a one-year term.","length":329,"tagName":"p"},{"type":"text","content":"Dr. Gerd Zettlmeissl is a vaccine expert and Biotech Entrepreneur with more than 30 years of scientific and leadership experience in the biopharmaceutical industry. He currently serves on the Board of Directors of several non-profit organizations and biotech companies, including Medigene and MinervaX.","length":302,"tagName":"p"},{"type":"text","content":"Additionally, the term of office of Deloitte & Associés as Statutory Auditor was renewed for a period of six years.","length":119,"tagName":"p"},{"type":"text","content":"During the meeting, Valneva’s management also confirmed the Company’s full-year 2025 financial guidance.","length":104,"tagName":"p"},{"type":"text","content":"The AGM’s voting results will be made available in the “Investors & Media” section of Valneva’s corporate website in the coming days.","length":137,"tagName":"p"},{"type":"text","content":"About Valneva SEWe are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expe...